STAGE III LUNG CANCER AJCC V8

This early-phase study tests a personalized vaccine made from each patient's unique tumor markers (neo-antigens) to help their immune system fight cancer. It includes up to 25 adults with advanced melanoma, breast cancer, or non-small cell lung cancer that has not responded to st…

This study tests whether adding a precise, high-dose radiation treatment (SBRT) to the standard combination of radiation, chemotherapy, and immunotherapy can help people with locally advanced lung cancer live longer. About 474 adults whose cancer has spread to nearby lymph nodes …

This early-phase trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced or spreading non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive…

This study tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has started to grow again after chemoradiation and durvalumab. About 51 adults will receive this combination.…

This study tests whether combining two targeted drugs—sotorasib and trastuzumab deruxtecan—is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 37 adults whose cancer has spread and who have already tried other tr…

This study tests whether adding the anti-inflammatory drug diclofenac can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults will receive diclofenac alongside their current immun…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests whether adding GT103 to the immunotherapy drug pembrolizumab can help people with a specific type of advanced lung cancer (STK11 mutant NSCLC) that has stopped responding to pembrolizumab alone. About 28 adults whose cancer has spread will receive both drugs to s…

This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage and cancer development. The goal is to see if this approach can stop lu…

This study tests whether a home-based breathing exercise program can help people who have finished treatment for early-stage lung cancer (stages I-III) feel less breathless, less tired, and more active. About 100 survivors will do breathing exercises at home for several weeks. Re…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, as well as for their family caregivers. About 400 patient-caregiver pairs will take part…

This study looks at whether getting immunotherapy in the morning or afternoon makes it work better for people with advanced or spreading solid tumors. The body's internal clock (circadian rhythm) may affect how the immune system responds. Researchers will compare progression-free…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track heart injury and fitness in 100 patients receiving treatment tailored to their individual risk. The goal is to learn if personalized planning can reduce heart problem…

This study tests a conversation aid that helps lung cancer patients and their doctors share decision-making about treatment. About 100 patients with non-small cell lung cancer will use the tool during appointments, and researchers will measure how involved patients feel and how s…

This study looks at two different ways surgeons cut blood vessels during lung cancer surgery. The goal is to see if tying off the vein first (instead of the artery) reduces the amount of tumor DNA released into the bloodstream. About 100 adults with early-stage lung cancer will h…